Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]-NW-3509 in Healthy Males
NCT03446274Phase 1Unknown
- Sponsor
- Newron Pharmaceuticals
- Start
- Apr 2018
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of evenamide in schizophrenia, mania and bipolar disorder (BD), sponsored by Newron Pharmaceuticals. Primary endpoint: Metabolic profiling for NW-3509 at 15 days. Status: unknown.
02
Drugs
evenamide
03
Conditions
schizophreniamaniabipolar disorder (BD)
Beyond the preview
Go deeper on NCT03446274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03446274.